Biomarkers for Hepatobiliary Cancers
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The clinical management of primary liver cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) has significantly changed in the last 3 years. The introduction of systemic therapies, including immune‐based therapies and biomarker‐driven therapies, has significantly improved survival, particularly in patients at advanced stages of disease. Survival is still poor, and projections from the World Health Organization underscore the need to improve outcomes in these patients. Biomarkers have emerged as powerful tools for the diagnosis, prognosis, and prediction of treatment responses to improve patient stratification and maximize clinical benefits. Recent advances in understanding the molecular alterations of HCC have not yet translated into biomarkers. Some reasons for the lack of progress are the absence of druggable mutations in the majority of liver cancers and the significant heterogeneity of the disease. In contrast, several therapeutic targets have been identified in CCA, and biomarker‐driven therapies are currently under evaluation in phase 2/3 clinical trials. Here, we summarize the status on biomarker development for HCC and CCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationVillanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Self-citationEl-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 1×
“Proposed biomarkers of response to CPI include PD1 ligand (PDL1) expression, tumor mutational burden,(42) aneuploidy,(43) and gene signatures.”
BackgroundDetection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · cited 1×
“(37) Despite the promising activity of the programmed death-1 (PD1) immune checkpoint inhibitors (CPIs) nivolumab(38) and pembrolizumab(39) in phase 2 with tumor responses nearing 20%, the corresponding phase 3 trials failed to meet their primary endpoint.”
BackgroundIDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · cited 1×
“They induce an abnormal methylation profile characterized by DNA methylation at the CpG islands (“CpG island methylator phenotype”).(52,56) Interestingly, induction of IDH1 or IDH2 mutation in liver progenitor cells blocks hepatocyte differentiation and induces iCCA underlying the cell plasticity during liver carcinog…”
BackgroundSchulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Self-citationFinn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626 · cited 3×
“Several risk factors have been identified, such as primary sclerosing cholangitis, liver fluke infection, diabetes type 2, obesity, hepatitis B, hepatitis C, and cirrhosis.(51) However, most CCAs were not associated with known risk factors.”
BackgroundGenetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325 · cited 2×
“The nonproliferation class is characterized by activation of the WNT canonical pathway, mostly through mutations in CTNNB1, and gene expression profiles resembling hepatocyte lineage.(27,28,30) Currently, these classes do not inform treatment decisions.”
BackgroundSelf-citationIdentification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976 · cited 1×
“Proposed biomarkers of response to CPI include PD1 ligand (PDL1) expression, tumor mutational burden,(42) aneuploidy,(43) and gene signatures.(44) Activation of the WNT pathway has also been suggested as a biomarker of primary resistance to CPI in HCC.”
BackgroundSelf-citationRuiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912 · cited 5×
“In addition to molecular classification associated with outcomes, numerous prognostic signatures have been reported in HCC.(31,32) Also, gene signatures derived from the adjacent nontumoral tissue have shown prognostic predictive capacity in HCC.(12,33) An integrative analysis of all these signatures in the same cohor…”
BackgroundInfluentialSelf-citationFocal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Self-citationHarding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma
Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M., Forgues, M., Pomyen, Y., Bhudhisawasdi, V., Lertprasertsuke, N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.009 · Cited by 434
Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316408 · Cited by 326 · cited 1×
“The companion biomarker study of the STORM trial failed to validate any of the gene signatures tested as predictors of recurrence in these patients,(35) which suggests that prospective validation is key to establishing the predictive capacity of any biomarker.”
Self-citationBorger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
Moeini, A., Torrecilla, S., Tovar, V., Montironi, C., Andreu-Oller, C., Peix, J., Higuera, M., Pfister, D., Ramadori, P., Pinyol, R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.028 · Cited by 92
Cited by
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Metadata
- Authors
- Nault, J., & Villanueva, A.
- Venue
- Hepatology
- Published
- 2020-11-29
- Volume
- 73
- Issue
- S1
- Pages
- 115-127
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3005987050
- Cited by
- 178
- References
- 23
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.